Literature DB >> 2849222

A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial.

D R Snydman1, B G Werner, N L Tilney, R L Kirkman, E L Milford, S I Cho, H L Bush, A S Levey, T B Strom, C B Carpenter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2849222

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  8 in total

1.  Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin.

Authors:  Ashley E Fouts; Pamela Chan; Jean-Philippe Stephan; Richard Vandlen; Becket Feierbach
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

Review 2.  Current status of renal transplantation.

Authors:  M G Suranyi; B M Hall
Journal:  West J Med       Date:  1990-06

Review 3.  Opportunistic infections in children following renal transplantation.

Authors:  W E Harmon
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

4.  Comparison of FK-506 and cyclosporine regimens in pediatric renal transplantation.

Authors:  D Ellis; R Shapiro; M L Jordan; V P Scantlebury; N Gilboa; L Hopp; N Weichler; A G Tzakis; R L Simmons
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

5.  Pharmacokinetics of ganciclovir in renal transplant children.

Authors:  E Jacqz-Aigrain; M A Macher; H Sauvageon-Marthe; P Brun; C Loirat
Journal:  Pediatr Nephrol       Date:  1992-03       Impact factor: 3.714

Review 6.  Cytomegalovirus infection and disease after liver transplantation. An overview.

Authors:  R J Stratta; M S Shaeffer; R S Markin; R P Wood; A N Langnas; E C Reed; J P Donovan; G L Woods; K A Bradshaw; T J Pillen
Journal:  Dig Dis Sci       Date:  1992-05       Impact factor: 3.199

7.  Cytomegalovirus infections in renal transplant patients.

Authors:  X G Zhang; M K Chan
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

8.  Functional screening for anti-CMV biologics identifies a broadly neutralizing epitope of an essential envelope protein.

Authors:  Thomas J Gardner; Kathryn R Stein; J Andrew Duty; Toni M Schwarz; Vanessa M Noriega; Thomas Kraus; Thomas M Moran; Domenico Tortorella
Journal:  Nat Commun       Date:  2016-12-14       Impact factor: 14.919
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.